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Abstract
Background
Bronchiectasis is accompanied by chronic bronchial infection that may drive disease progres-
sion. However, the evidence base for antibiotic therapy is limited. DNA based methods offer
better identification and quantification of microbial constituents of sputum than standard clinical
culture and may help inform patient management strategies. Our study objective was to deter-
mine the longitudinal variability of the non-cystic fibrosis (CF) bronchiectasis microbiome in
sputum with respect to clinical variables. Eighty-five patients with non-CF bronchiectasis and
daily sputum production were recruited from outpatient clinics and followed for six months.
Monthly sputum samples and clinical measurements were taken, together with additional sam-
ples during exacerbations. 16S rRNA gene sequencing of the sputum microbiota was suc-
cessful for 381 samples from 76 patients and analysed in conjunction with clinical data.
Results
Microbial communities were highly individual in composition and stability, usually with limited
diversity and often containing multiple pathogens. When compared to DNA sequencing, micro-
bial culture had restricted sensitivity in identifying common pathogens such as Pseudomonas
aeruginosa, Haemophilus influenzae, Moraxella catarrhalis. With some exceptions, community
characteristics showed poor correlations with clinical features including underlying disease,
antibiotic use and exacerbations, with the subject showing the strongest association with com-
munity structure. When present, the pathogens mucoid Pseudomonas aeruginosa and Hae-
mophilus influenzae may also shape the structure of the rest of the microbial community.
Conclusions
The use of microbial community analysis of sputum added to information from microbial cul-
ture. A simple model of exacerbations driven by bacterial overgrowth was not supported,
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Data Availability Statement: Sequence data has
been submitted to the European Nucleotide Archive
and is available under accession number
PRJEB14304 and sample accessions ERS1201047
to ERS1201427. In addition, the denoised reads,
OTU table and clinical data are available to
download at [http://lungen.bioinformatics.ic.ac.uk/
data/microbiome_LAMB_bronchiectasis/] and at
BioStudies accession S-BSST1 [https://www.ebi.
ac.uk/biostudies/studies/S-BSST1/]. The clinical
data is also available as S1 Table.
suggesting a need for revision of principles for antibiotic therapy. In individual patients, the
management of chronic bronchial infection may be improved by therapy specific to their
microbiome, taking into account pathogen load, community stability, and acute and chronic
community responses to antibiotics.
Introduction
Bronchiectasis is characterised by abnormal dilated thick-walled bronchi and is often accom-
panied by chronic bronchial infection. Patients with advanced disease may produce copious
volumes of purulent sputum and lung function may be severely and progressively impaired.
The prevalence of non-CF bronchiectasis in the US has been estimated at 272 per 100 000 per-
sons over 75 years of age and hospitalisation rates are increasing [1].
Although chronic infection with episodes of exacerbation may drive the progression of
bronchiectasis, the evidence base for antibiotic therapy is limited [2]. An underlying assump-
tion is often that exacerbations are driven by the overgrowth of a particular microbial species,
although mixed pathogen colonisations are recognised. Antibiotic choice in current practice is
initially empirical until sputum cultures are obtained and then directed by isolated organism
[2].
Standard microbial cultures are selective, identifying a restricted range of bacterial species
in clinical samples. Molecular, culture-independent, techniques such as 16S rRNA gene
sequencing have been shown to detect a much greater variety of microbes from the same speci-
mens as standard culture techniques [3–9].
In order to understand the potential impact of culture-independent techniques on the man-
agement of chronic bronchial infection, we have carried out a prospective six-month study of
patients with computerised tomography (CT) -defined bronchiectasis attending clinics at the
Royal Brompton Hospital, London. Recruited patients were studied at monthly intervals and
during any exacerbations.
We present here the results of quantification of the bacterial burden by quantitative poly-
merase chain reaction (qPCR) of the 16S rRNA gene and community analyses, comparing
them to clinical outcomes and microbiological cultures.
Microbial diversity reflects the number of species, their presence and their abundance,
in a study. Higher levels of diversity are associated with resilience of microbial communities
to invasion, and may characterise human health. We have therefore examined associations
with the number and proportions of species in individual patients (captured by measures
of α-diversity), and with the community structure across patients (reflected in β-diversity
statistics).
Some of this work has been presented before in the form of an abstract and presentation at
the American Thoracic Society International Conference 2015 [10] and pre-print at BioArxiv.
org [11]
Material and methods
Participants
We recruited patients with CT-defined non-CF bronchiectasis and daily sputum production
between December 2010 and May 2011 at the Royal Brompton Hospital, a tertiary referral cen-
tre. Patients gave their full informed written consent and the study was approved by South
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GENTAMICIN NEB; MeroIVPPx, Prophylactic
MEROPENEM IV; MinoPPx, Prophylactic
MINOCYCLINE; MoxiPPx, Prophylactic
West London Research Ethics Committee under reference number 10/H0801/53. Patients had
all previously been screened according to the British Thoracic Society bronchiectasis guide-
lines[2]. Patients had monthly research visits at which fresh sputum samples were collected
and spirometry and clinical assessment performed. Body mass index (BMI) measurements
were taken only at the initial visit. Patients were encouraged to attend the centre for a sus-
pected exacerbation and to provide a further sputum sample. An exacerbation was defined as
an acute deterioration with worsening local symptoms (increased cough, sputum volume, vis-
cosity, purulence, breathlessness) and/or systemic upset and the physician determined need
for antibiotics as per the BTS bronchiectasis guidelines. The clinical state for each sample was
defined as baseline (B), exacerbation (E), treatment (T), or recovery (R) as previously pub-
lished [12]. Briefly, B was defined as well or mild increase in respiratory symptoms, no doctor
defined respiratory exacerbation, not hospitalised, not on episodic antibiotics for more than
30 days. E was defined as a doctor defined respiratory exacerbation, the sample was prior to
the start of episodic intravenous (IV) or oral antibiotics, not on episodic antibiotics for more
than 30 days. T was defined as on IV or oral episodic antibiotics for treatment of doctor
defined respiratory exacerbation whilst R was defined as off episodic antibiotics for less than
30 days and may or may not be back to baseline clinical state. Patients recorded antibiotic use
during the six-month period. Patients gave their full, informed, written consent and the study
was approved by South West London Research Ethics Committee 1 under reference number
10/H0801/53
Sputum samples underwent the standard clinical microbiology and reporting for non-CF
sputum samples (Chocolate agar and Blood agar at 5% CO2 and 37˚C, MacConkey agar at
37˚C). Samples for molecular testing were stored frozen at -80˚C prior to DNA extraction
which was performed using the FastDNA Spin Kit for Soil (MP Biomedicals, Santa Ana, CA,
USA) as per manufacturer instructions (including 55˚C incubation at elution). Bead-beating
was performed at 6800 rpm for two cycles of 30 seconds (Precellys, Bertin Technologies, Mon-
tigny-le-Bretonneux, France).
Molecular microbiology
Quantitative PCR of each extracted DNA was performed in triplicate using the Viia7 Real
Time PCR system (Life Technologies, Waltham, MA, USA) and the primers 520 F AYT GGG
YDT AAA GNG and 802 R TAC NVG GGT ATC TAA TCC targeting the 16S rRNA gene V4
region. Samples that failed to amplify were repeated twice to confirm the result. Reaction con-
ditions are available in S1 Appendix.
16S rRNA gene amplification of the V3–V5 region was performed in quadruplicate using
adapted primers 357F/926R [13] with 12 bp barcodes included in the reverse primer [14] and
454 sequencing adaptors A and B included in the reverse and forward primers respectively.
Sequencing was performed on a Roche 454 (454 Life Sciences, Branford, CT, USA) and further
methodology and sequence processing is detailed in S1 Appendix. The resulting operational
taxonomic unit (OTU) table of 381 samples and 352 OTUs was used for all subsequent analy-
ses and imported to the R statistical environment as a PhyloSeq [15] object, along with a mid-
point rooted FastTree phylogenetic tree. A cross-sectional dataset of 72 samples and 194 OTUs
was produced by sub-sampling the first baseline classified (B in the BETR scheme) sample
available from each patient in PhyloSeq. Sequence data has been submitted to the European
Nucleotide Archive and is available under accession number PRJEB14304 and sample acces-
sions ERS1201047 to ERS1201427. In addition the denoised reads, OTU table and clinical data
are available to download at http://lungen.bioinformatics.ic.ac.uk/data/microbiome_LAMB_
Microbiota in non-CF bronciectasis
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bronchiectasis/ and at BioStudies accession S-BSST1 https://www.ebi.ac.uk/biostudies/studies/
S-BSST1/. The clinical data is also available as S1 Table.
For comparisons with microbial culture, OTUs were selected by either being the most
abundant OTU with similar identification (Pseudomonas, Moraxella, Streptococcus), the only
OTU identified as that genus (Stenotrophomonas, Proteus) or the representative read positively
identified by phylogenetic analyses as the same species (Haemophilus influenzae).
Statistics
Statistical analysis was performed in the R statistical environment (version 312, [16]).
Species richness, Pielou’s evenness, Shannon’s Diversity Index, and Inverse Simpson’s
Index were calculated for each sample. Diversity metrics were assessed for normality using
Shapiro-Wilk’s tests and quantile-quantile plots (S1 Fig). Shannon’s Diversity Index, Inverse
Simpson’s Index and Pielou’s evenness were tested against variables using Wilcoxon Signed
Rank and Kruskal Wallis Rank Sum tests. Species richness was normally distributed and tested
using Student’s T-test and analysis of variance (ANOVA). Spearman’s Rank correlations were
used for continuous variables (e.g. FEV1, BMI). Bacterial load as determined by qPCR was
normally distributed and paired Student’s T-test used; to do so, the first available consecutive
samples of each combination of BETR class were used from each patient in this analysis i.e.
B-B, B-E, B-T and B-R. If there was no available B sample in the month prior to another class,
this pair was dropped.
For the Adonis permutational multivariate ANOVA (PERMANOVA) analyses, all variables
were tested independently in the cross-sectional dataset. Those that proved to be significant
were taken forward for further testing together in a larger model. Non-significant variables
were backward removed from the models and samples with missing data were removed list
wise. The order of the variables remaining was also tested as this can influence a PERMA-
NOVA and the final model explains the maximum variance possible in the most limited num-
ber of variables. The final variables included in order were: isolation of mucoid Pseudomonas
aeruginosa, isolation of Haemophilus influenzae, prophylactic treatment with Colistin and iso-
lation of Staphylococcus aureus and a more detailed description of the model and R2 values can
be found in the S1 Appendix. PERMANOVA was also used with the longitudinal dataset, but
only to look at the variance explained by subjectID as it is not suitable for repeated measures.
A version of this manuscript was archived on the pre-print server BioRxiv[11] and some of
the data was presented at the American Thoracic Society Conference[10].
Results
Patient characteristics
Eighty-five subjects were recruited and produced 467 sputum samples. Post DNA and sequenc-
ing quality controls, 381 samples from 76 subjects were included in the longitudinal analysis. A
cross-sectional dataset was created by taking the first baseline sample of 72 subjects. The remain-
ing four subjects had only exacerbation, treatment or recovery samples. The aetiology of the
bronchiectasis was most commonly idiopathic (47%) or post-infective (25%) (Table 1 and Fig 1).
In general, the disease was severe (median baseline FEV1% predicted 63%, IQR 54% to 82%).
Baseline microbiome
DNA was successfully extracted, PCR amplified and amplicons sequenced for 411 samples, yield-
ing a total of 956,269 high-quality reads after quality control (see S2 Fig in the online data supple-
ment). We chose a randomly re-sampled threshold of 451 reads to ensure no bias between
Microbiota in non-CF bronciectasis
PLOS ONE | DOI:10.1371/journal.pone.0170622 February 7, 2017 4 / 17
Brycanyl, Respiratory medication: BRYCANYL;
Serevent, Respiratory medication: SEREVENT;
Theo, Respiratory medication: THEOPHYLLINE;
O2, Respiratory medication: OXYGEN.
sample comparisons (S3 and S4 Figs). The number of reads used discriminates very well between
samples and individuals and rarefaction curves reach an asymptote indicating sufficient sam-
pling (S1 Appendix).
For the cross-sectional baseline data set, phylogenetic analyses showed the presence of 352
OTUs, 150 of which were present in more than one subject with 21 being present at an overall
abundance > 05%. Haemophilus_542 was the most abundant OTU overall, followed by Pseu-
domonas_aeruginosa_915 and Streptococcus_338 (Fig 1B). Using phylogenetic analysis we
were able to confirm the Haemophilus_542 OTU to represent H. influenzae (see S5 Fig in the
online data supplement). This approach was also attempted for Streptococcus_338, but the
resulting phylogenetic trees were unable to discriminate Streptococcal OTUs at the species
level (data not shown).
The most common organisms detected in sputum by clinical culture, for subjects for whom
we also had 16S rRNA gene sequence data, were Pseudomonas aeruginosa (453% of subjects),
Staphylococcus aureus (213%) and Haemophilus influenzae (147%).
We compared 16S rRNA gene sequences with microbial culture by classifying OTUs as
either present or absent in a subject. Comparison with DNA sequences and culture, with
sequence as the putative gold standard, suggested that the calculated accuracy of cultures for
P. aeruginosa was 71% and for H. influenzae was 62%, although the sensitivities were only 52%
and 18%, with disagreement commonly observed in culture negative, 16S rRNA gene positive
samples (Table 2). The apparent false discovery rate relative to 16S rRNA gene sequencing for
Table 1. Patient Demographics.
Baseline Cross-Sectional Longitudinal
Number of Subjects 72 76
Number of Samples 72 381
Sex n (%) Female 49 (68)
Median Age (Inter Quartile Range) 62 (55–68)
Median BMI (IQR) 1 94 (1 69–2 225)
Smoking Status n (%)
Current 0 (0)
Ex 17 (24)
Never 47 (65)
Unknown 8 (11)
Cause of bronchiectasis n (%)
Idiopathic 34 (47)
Post-Infection 18 (25)
Allergic Bronchopulmonary Aspergillosis (ABPA) 8 (11)
Primary Ciliary Dyskinesia (PCD) 7 (10)
Immunodeficiency 2 (3)
Other 3 (4)
Lung Function
Median percent predicted FEV1 (IQR) 63 (54–82)
Median percent predicted FVC (IQR) 79 (69–84)
Clinical status (BETR Category) n (%)
Baseline (B) 72 (100) 261 (69)
Exacerbation (E) 36 (9)
Treatment (T) 17 (4)
Recovery (R) 67 (18)
doi:10.1371/journal.pone.0170622.t001
Microbiota in non-CF bronciectasis
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Fig 1. 1A. Demographics of the non-CF bronchiectasis cohort. Indicating distribution of (from left to right, top to bottom): the cause of
bronchiectasis; FVC percent predicted (red line indicates 50%); subject age; subject sex; BMI class; FEV1 percent predicted (red line indicates
50%); smoking status; and whether subject has previously cultured P. aeruginosa. 1B. Distribution of OTUs within the cohort. Abundance is
the total number of reads assigned to an OTU from any sample. Prevalence is how often an OTU is detected in samples. Haemophilus_542
Microbiota in non-CF bronciectasis
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culturing P. aeruginosa was 11%, and for S. aureus was 64%. There was poor accuracy (9%)
and sensitivity (4%) for Streptococcal OTUs compared with culture.
Alpha-diversity by all measures (Shannon Diversity Index, Inverse Simpsons Index, species
richness and evenness) was significantly lower if the subject was receiving prophylactic antibi-
otics, or if any organism had been isolated from the sample, or if mucoid P. aeruginosa had
been isolated (Fig 2A). The patients’ gender, treatment with steroids, age, forced expiratory
volume in one second (FEV1), forced vital capacity (FVC), body mass index (BMI), and the
number of years since first P. aeruginosa isolate were not associated with diversity.
β-diversity
Bray-Curtis dissimilarity was calculated in order to compare the relationship between commu-
nities of baseline samples from each individual and clinical factors We constructed PERMA-
NOVA models of the baseline cross-sectional dataset to test the effect of individual variables
on between-sample β-diversity. Variables were removed from the model if they were no longer
significant, optimising the fewest number of variables that together explained the highest pro-
portion of variance. The variance of diversity was significantly related to treatment with pro-
phylactic Colistin (R2 004, P = 0008) and by isolation of mucoid P. aeruginosa (R2 014,
P< 0001), H. influenzae (R2 007, P< 0001) and S. aureus (R2 004, P = 0013). These vari-
ables together accounted for 29% of the total variance in the community structure.
Longitudinal analysis
There were 122 infective exacerbations recorded by the 64 patients that completed follow up
over the 6-month period. Forty-one patients had two or more exacerbations over 6 months,
with 14 patients having no exacerbations and 9 patients having only one.
There was no significant difference in the exacerbation rate in patients on prophylactic anti-
biotics or patients with or without P. aeruginosa. In total, 37 exacerbations coincided with
clinic visit. 18 (50%) of these were not accompanied by the growth of bacteria in culture,
was most abundant, contributing 16% of all reads in the dataset. Streptococcus_338 was most prevalent and was found to some degree in
every sample.
doi:10.1371/journal.pone.0170622.g001
Table 2. Comparison of 16S rRNA gene sequences and microbial culture.
Culture ID OTU ID Both +ve Both -ve Culture
-/OTU +
Culture +
/OTU -
Accuracy False Discovery
Rate
Sensitivity
Pseudomonas aeruginosa Pseudomonas_915 106
(28%)
164
(43%)
97 (26%) 13 (3%) 71% 11% 52%
Haemophilus influenzae Haemophilus_542 31 (8%) 203
(53%)
146 (38%) 0 (0%) 62% 0% 18%
Moraxella catarrhalis Moraxella_945 16 (4%) 313
(82%)
51 (13%) 0 (0%) 87% 0% 24%
Staphylococcus aureus Staphylococcus_300 20 (5%) 313
(78%)
32 (8%) 35 (8%) 83% 64% 38%
Stenotrophomonas
maltophilia
Stenotrophomonas_
401
11 (3%) 323
(85%)
46 (12%) 0 (0%) 88% 0% 19%
Proteus vulgaris Proteus_1088 1 (03%) 370
(97%)
8 (2%) 1 (03%) 98% 50% 11%
Streptococcus
pneumoniae
Streptococcus_338 13 (3%) 23 (6%) 343 (90%) 1 (03%) 9% 7% 4%
doi:10.1371/journal.pone.0170622.t002
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despite non-usage of antibiotics during the previous 30 days. Only 4/37 (11%) of the exacerba-
tion samples were associated with isolation of a bacterium not seen in prior samples.
We used 16S rRNA gene quantitative PCR to measure the total bacterial load in the sam-
ples. The median copy number was 22 x108 per ml of sputum at baseline (IQR 48 x 107–86 x
108). We found no significant difference in bacterial load between the baseline, exacerbation,
treatment or recovery samples (see S6 Fig in the online data supplement).
There was no significant difference in any diversity measure between exacerbation samples
and paired baseline (n = 13), treatment (n = 5) or recovery samples (n = 21) from the month
immediately prior to the exacerbation (see S7 Fig in the online data supplement). There was
also no difference in any diversity measure between exacerbation samples and those immedi-
ately following recovery.
A multivariate ANOVA showed that 596% of the total variation in longitudinal β-diversity
could be explained by the subject the sample was from, compared to 58% for the underlying
disease (Fig 2B).
We calculated a per subject median Bray Curtis dissimilarity for those with 3 or more sam-
ples to give an individual range of diversity in different samples from individual subjects. A
high value indicated that the microbial communities changed from month to month in relative
abundance and membership, and a low value indicated that samples from the same subject
were similar. The median dissimilarity was selected in order to reduce sensitivity to outlying
data points and all possible pairs of dissimilarities were included. We observed a wide range of
stability for the normally distributed metric (range 012 to 098; mean = 058, median = 060)
(Fig 2C).
The stability metric did not correlate significantly with clinical characteristics including
BMI, prophylactic antibiotic treatment, number of exacerbations, average lung function
(FEV1 [forced expiratory volume] percent predicted, FVC [forced vital capacity] percent pre-
dicted), underlying cause, and carriage of P. aeruginosa. Additionally, there was no difference
in this metric between patients who did or did not change clinically during the study.
Given the high individuality of the microbial communities, we produced per subject plots
of the OTU relative abundances alongside the clinical data and quantitative PCR of the 16S
rRNA gene as a proxy for bacterial load. A wide spectrum of community compositions, stabil-
ity, and pathogen load were observed, (Fig 3A to 3D for examples and S8 Fig in the online data
supplement for all other subjects).
Discussion and conclusion
The study shows substantial complexity in the airway microbiome in patients with chronic
bronchial infection, with frequent mixed infections and potentially important discrepancies
between DNA sequencing results and classical clinical culture. The structure of microbial com-
munities within patients was highly individual, relating only weakly to underlying disease, and
often stable over the six months of the study despite the use of antibiotics and changes in clini-
cal state.
The differences between culture and 16S rRNA gene sequencing show that the common
complexity of pathogen growth is captured incompletely by standard microbial culture. In par-
ticular the presence of H. influenzae appears under-recognised by culture, and Pseudomonas
spp. and S. aureus were at times present in culture and not detected by sequencing. This may
reflect the capacity of culture to isolate pathogens when they are present in very low numbers,
and the ability of Pseudomonas spp. and S. aureus to outgrow other organisms in culture. Since
the discrepancy in S. aureus was most marked, primer sequences were checked for specificity
for this group of organisms and found to have 100% identity to the S. aureus target. Inefficient
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Fig 2. 2A. Boxplots of species richness for cross-sectional baseline samples comparing clinical categories. Notches indicate 95% confidence interval.
P values were calculated using Welch’s T test. 2B. Non-metric multi-dimensional scaling plot of Bray-Curtis dissimilarity. This ordination plot visually
represents the Adonis results. The plot has been split by underlying cause of non-CF bronchiectasis to reduce over-plotting and to enable clearer
visualisation of clustering of points, although each panel can be considered to be directly overlaid upon one another. Each point represents a sample
and the larger the distance between points the larger the difference in community structure of those samples. Samples from the same patient have the
same colour. Samples from the same patient tend to cluster together, illustrating the high individuality. There is some separation of points evident in the
underlying diseases, e.g. Post-infectious samples tend to be present in the bottom right of the plot, PCD top right, ABPA central bottom and idiopathic
more widely distributed. 2C. Histogram of the median per patient Bray Curtis dissimilarity. Bray Curtis dissimilarity was calculated for each patient with
more than 3 samples and ranged from 012 to 098. The embedded stacked bar plots illustrate the patients at the two extremes, least diverse and most
stable to most diverse and variable.
doi:10.1371/journal.pone.0170622.g002
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DNA extraction can be of concern with Gram positive organisms, although the bead-beating
approach has been employed widely and in our hands efficiently lyses Mycobacteria and fungi
[17]. It has also been validated for endospore extraction, so we do not believe that inefficient
DNA extraction has occurred here. It is possible however that relatively inefficient amplifica-
tion of 16S rRNA gene sequences from genomic DNA of S. aureus against a mixed template
background may have occurred.
A limitation of 16S rRNA sequencing is that particular OTUs may not define bacterial spe-
cies, best exemplified by the inability to identify Streptococcus pneumoniae or S. mitis among
the streptococcal OTUs. It is likely that the discrepancy between culture and the 16S rRNA
gene sequencing is caused by the summing of multiple different Streptococcal species, includ-
ing common respiratory commensals, into a single OTU. OTU analysis also cannot be used to
define pathogenicity, and does not give information about antibiotic susceptibility.
The microbiome in our patients may reflect their advanced disease and treatment with multi-
ple courses of antibiotics over many years. Although the literature does not yet provide a clear
meta-analysis of the normal airway microbiome, the distribution and diversity of OTUs in these
patients seems to differ markedly from that seen in normal subjects or those with asthma or
chronic obstructive pulmonary disease (COPD), where Gram negative anaerobes such as Prevo-
tella or Veilonella spp. may make up to ~30% of OTU abundance [4,8,18]. Nevertheless, these
species remained amongst the most prevalent and may be non-pathogenic members of the com-
mensal microbiota or may have an involvement in disease processes[19].
It is unclear whether the lower abundance of these organisms in our patients is a result of the
presence of more abundant organisms, competition with other organisms such as P. aeruginosa
and H. influenzae, or whether it follows selection by treatment with antibiotics. It is possible that
depletion of the commensal community may itself facilitate early pathogen introduction to com-
munity and dominance. In chronic obstructive pulmonary disease, acquisition of a new bacterial
strain has been associated with exacerbations [20]. Here we lack strain level resolution, although
new OTUs could only rarely be seen associating temporally with exacerbations. For example, Sub-
ject 15 Pseudomonas_aeruginosa_915 takes over from Streptococcus_338 at exacerbation, in sub-
ject 24 Stenotrophomonas_401 from Pseudomonas_aeruginosa_915 whilst there is an increase in
Staphylococcus_300 in patient 67.
Fig 3. Selected subject plots. Each subject is represented by four plots, from top to bottom: clinical variables
including antibiotic treatment, growth of microorganisms on clinical culture and B,E,T,R category; Lung function
as FEV1% predicted (red), FVC % predicted (green) with 30% and 80% represented by the grey dotted line;
bacterial load as measured by 16S rRNA gene qPCR in copies per ml of sputum with the detection limit of the
assay indicated by the grey dotted line; stacked barplots of the OTUs present in each sample. Colour coding for
top 26 OTUs consistent between plots, with greyscale used for the remaining OTUs. Rare OTUs in each plot
are summed as “Other”. 3A Subject 12: 68 yr old male with ABPA, normal BMI and 2 exacerbations during the
study period. The patient had the highest median Bray-Curtis dissimilarity. Streptococcus_693 was the most
abundant OTU in every sample (although not dominant) but other OTUs changed in relative abundance from
sample to sample. Bacterial load changed substantially over the sampling period. 3B Subject 75: 64 yr old
female, post-infectious, underweight and 2 exacerbations during the study period. The patient had the lowest
median Bray-Curtis dissimilarity and most stable microbial community, dominated by Haemophilus_542,
despite two clinical exacerbations and treatment with Augmentin. Bacterial load varied by two orders of
magnitude from 107 to 109 copies per ml of sputum. 3C Subject 24: 60 yr old male, unknown bronchiectasis
cause, normal body mass index (BMI) and 2 exacerbations during the study period. The patient did show
changes in bacterial community that coincided with clinical states, such as an exacerbation at time point Be
associated with a large increase in abundance of Stenotrophomonas_401. Antibiotic treatment resolved the
exacerbation and Stenotrophomonas_401 proportions returned to lower levels. 3D Subject 16: 65 yr old male
with ABPA, normal BMI and 2 exacerbations during the study period. The patient had an exacerbation at
samples D and E, with Pseudomonas_aeruginosa_915 initially dominant being replaced by Haemophilus_542.
The proportion of Haemophilus_542 and bacterial load in the samples increased, suggesting active growth of
Haemophilus_542 that was supported by coincident clinical culture of H. influenzae.
doi:10.1371/journal.pone.0170622.g003
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Our observation that prophylactic antibiotics correlated with reduced alpha-diversity sup-
ports a community level impact of prophylactic therapy. No individual antibiotics correlated
with alpha-diversity; however a large number of different antibiotics were used within the
cohort and the study period. Trials of individual antibiotics would be a more appropriate
method of assessing individual antibiotic treatment effects on variability. There was however
no correlation of alpha or beta diversity or bacterial load with important clinical parameters
such as severity or duration of disease, suggesting that analyses of diversity are not simply a
reflection of disease severity and that they should be used alongside the recognition and enu-
meration of pathogens.
The culture of mucoid P. aeruginosa was associated with changes in community structure,
which might be due to the impact on the local environment in the lung of this phenotype or
could be a marker of longer colonisation as mucoidy is associated with chronic colonisation
[21].
Our finding that the bacterial community relates poorly to clinical state supports the results
of longitudinal studies of patients with Cystic Fibrosis [12,22–25]. Overall in these studies no, or
poor associations with clinical state are seen when taking each cohort as a whole. However, as we
have also demonstrated here, in subsets of patients associations can be seen. CF is a much more
clinically defined disease than non-CF bronchiectasis, though strong individuality in the micro-
biota may also mask the influence of the microbiota on clinical state. Viral PCR is not routinely
performed in these patients, so we are unable to rule this out as associated with exacerbations.
Fungal culture is routinely performed and one subject did culture an Aspergillus at exacerbation
although this was not treated and was also present in the following recovery sample when the
patient was no longer exacerbating and completing courses of antibiotics. This result also under-
lines the complexity of these disease processes as other factors such as undiagnosed comorbidi-
ties, viral and fungal infection, environmental exposure and the immune response are all also
likely to all also play a role to a greater or lesser extent in each subject.
The present study included a number of different underlying etiologies of non-CF bronchi-
ectasis in order to allow comparison of these and to assess whether the microbial communities
supported these clinical classifications. After taking into account the strong per subject differ-
ences in microbial communities, a small proportion of the variance could be ascribed to etiol-
ogy. This might indicate that in larger studies stratification by etiology would reduce the
variance and increase power to detect disease-specific effects.
Here we find that H. influenzae and P. aeruginosa are the two most common and dominant
pathogens by 16S rRNA gene sequencing. In our PERMANOVA model isolation of mucoid P.
aeruginosa or H. influenzae had the greatest influence on community structure as a whole.
Changes in the microbiota composition have also been demonstrated after prophylactic treat-
ment with erythromycin in a more homogenous and milder group of bronchiectasis patients,
though only when considering individuals dominated by H. influenzae [26]. This suggests that
although underlying etiology can be important, the dominant organism present, irrespective
of etiology, has greater influence and could be targeted accordingly.
Discerning the impact of individual antibiotics was difficult in this dataset, given the
extremely individual microbiota and the range of different antibiotics used for prophylaxis,
exacerbation, and non-respiratory reasons. Colistin was the only antibiotic that had a signifi-
cant impact on community structure. It was the only nebulised antibiotic to be used frequently
within the cohort, so the impact of nebulisation, where a higher concentration of antibiotic is
expected local to the respiratory tract, is difficult to separate from the actions of Colistin itself.
The influence of Colistin on community structure is not independent of the influence of
mucoid P. aeruginosa as this antibiotic would be used to target the organism in this patient
group [27].
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We separated antibiotics into those given prophylactically for respiratory reasons, respira-
tory exacerbation antibiotics and non-respiratory antibiotics. Only a small number of non-
respiratory antibiotics were prescribed to study patients and as these are at a lower dose and
likely to have less influence on the microbial communities in the airways, these were not
included in the BETR definition.
Possible explanations for the poor correlation between the sputum microbiome and clinical
course include that the disease is driven by mucosal events that are poorly reflected in sputum,
or that the activity of the microbiome is changing independently of bacterial load (for example
through expression of virulence factors), or that exacerbations are being driven by virus or
fungal infections rather than bacteria. Our study was not designed to examine exacerbation
specifically, as its aim was to observe changes of the microbial community in a diverse non-CF
bronchiectasis cohort over time. Consequently, only a relatively small number of exacerbation
(E) or treatment (T, exacerbation with current antibiotic treatment) samples were obtained.
We were unable to obtain a full set of samples analysed by all methodologies from every
individual. As can be seen in the consort diagram (S2 Fig) this was due to subjects withdrawing
part way through the study, subjects being unable to expectorate sputum on a particular occa-
sion and insufficient material for analysis at the further methodological stages of 16S rRNA
gene sequencing. Lack of sputum expectoration was also an issue with T (treatment) samples
as treatment reduced sputum volume. As 16S rRNA gene qPCR was applied later than 16S
analyses it was only performed for subjects with sufficient sample remaining.
Sputum samples in some individuals revealed the same community every month for six
months, showing consistency of community structure. The variability in other patients might
result from a respiratory tract rendered inhomogeneous by advanced disease, which may con-
found a whole airway sample such as sputum [4,28]. More frequent sampling could establish
whether changes in the microbiota not coincident with clinical change were due to sampling
variability, community variability as a result of drivers with no clinical impact (e.g. competi-
tion between microorganisms) or clinical changes that occurred between visits and were not
captured. Longer and more frequent sampling may also allow the development and application
of more sensitive statistical and ecological methods that will also be of benefit. It is important
nevertheless that the number of patients and the period of time studied here is substantial
compared to previous studies of BX and other chronic suppurative lung diseases.
It is possible that serial sampling of the sputum microbiome with nucleic acid sequenc-
ing may be used to better therapeutic outcomes for patients with chronic bronchial infec-
tion. Given the extremely high individuality, longitudinal assessments of the individual
patient’s microbiota during periods of health may become the best control for managing
their exacerbations.
Diverse bacterial communities can be resistant to pathogen invasion, so prophylaxis with
more targeted antibiotics that maintain diversity might be beneficial. Our results suggest that
accurate profiling of the respiratory microbiome will lead to improvements in the understand-
ing of the role of prophylactic antibiotics on community diversity, accurate recognition of
pathogens and their interactions in complex communities, and better identification and treat-
ment of true infective exacerbations.
Conducting even larger studies that will allow stratification of patients by underlying eti-
ology, dominant pathogen and antibiotic treatment will increase power significantly and
may lead to identification of stronger links between clinical state and the microbiota pres-
ent. A number of inhaled antibiotics are in development for bronchiectasis and a better
understanding of their benefits and the consequences of their use on the microbial commu-
nity is needed.
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Supporting information
S1 Appendix. Containing supplementary methods and details of the PERMANOVA statis-
tical model.
(DOCX)
S1 Fig. Quantile-quantile plots and Shapiro-Wilks test results for the diversity metrics.
Species richness is confirmed to be normally distributed, while the other three measures, spe-
cies evenness, inverse Simpson’s index and Shannon’s diversity index are non-normally dis-
tributed.
(TIF)
S2 Fig. Diagram indicating how many patients were enrolled, how many samples were
taken and the fates of each sample during sample extraction, amplification, sequencing
and sequence processing.
(TIF)
S3 Fig. Ranked abundance curve of all samples sequenced indicating number of samples
lost for different levels of sequence depth.
(TIF)
S4 Fig. Rarefaction curves of species richness indicating that in all samples random-resam-
pling, “rarefaction” to 451 reads captures the diversity of the samples effectively.
(TIF)
S5 Fig. Phylogenetic tree of the representative read from the Haemophilus_542 OTU with
nearest neighbours from the Silva version 111 database indicates that this OTU represents
Haemophilus influenzae. Alignment positions 509 to 909 (Escherichia coli numbering) were
used to construct a neighbour joining tree of partial 16S rRNA gene sequences using ARBs
(ref) neighbour function with 500 bootstraps. Bootstrap values less than 50% are collapsed to
multi-furcations. The tree was rooted for display purposes with an outgroup consisting of Pro-
videncia spp., Morganella spp. and Proteus spp. The position of the Haemophilus_542 OTU is
highlighted in red.
(TIF)
S6 Fig. Boxplots of bacterial load by B,E,T,R category. There is no significant difference in
load. Samples with current treatment for exacerbation have the lowest median, though num-
bers of non-baseline samples are relatively low.
(TIF)
S7 Fig. Line plots of the change in Shannon’s diversity index difference between BETR cat-
egories. Baseline (B) samples are paired with samples taken the following month of each of the
categories. It is possible that within an individual more than one pair of immediately following
samples can be found, in this case, within each plot only the first from that subject was used.
(TIF)
S8 Fig. Subject plots. Stacked barplots of every subject with three or more samples. As with S3
Fig each subject is represented by four plots, from top to bottom: clinical variables including
antibiotic treatment, growth of microorganisms on clinical culture and B,E,T,R category; Lung
function as FEV1% predicted (red), FVC % predicted (green) with 30% and 80% represented
by the grey dotted line; bacterial load as measured by 16S rRNA gene qPCR in copies per ml of
sputum with the detection limit of the assay indicated by the grey dotted line; stacked barplots
of the OTUs present in each sample. Colour coding for top 26 OTUs is consistent between
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plots to allow comparison of the most common organisms; greyscale is used for the remaining
OTUs, which is consistent only within each plot as there are insufficient colours for this to be
possible across all plots. Rare OTUs in each plot are summed as “Other”.
(PDF)
S1 Table. An excel spreadsheet of the clinical data used in the analysis of the 16S rRNA
gene sequence data.
(XLSX)
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